We can’t show the full text here under this license. Use the link below to read it at the source.
Impact of GLP ‐ 1RA on the Risk of Adverse Liver Outcomes Among Patients With Alcohol‐Associated Liver Disease and Type 2 Diabetes
GLP-1RA treatment and risk of liver problems in people with alcohol-related liver disease and type 2 diabetes
AI simplified
Abstract
Among 14,730 patients, 2.2% had exposure to GLP-1RA.
- Patients taking GLP-1RA had a lower incidence of hepatic decompensation (22.4%) compared to those not taking it (32.2%).
- The incidence of hepatocellular carcinoma was significantly lower in GLP-1RA patients (0.3%) compared to non-GLP-1RA patients (3.9%).
- There was no significant difference in the incidence of portal hypertension or liver transplantation between the two groups.
- The overall incidence of was lower in the GLP-1RA cohort (12.0%) compared to the non-GLP-1RA cohort (21.0%).
- An absolute incidence risk reduction of 9.0% was associated with GLP-1RA use.
AI simplified
Key numbers
9.0%
Decrease in Incidence
Absolute incidence risk reduction with GLP-1RA use.
22.4%
Hepatic Decompensation Incidence
Incidence of hepatic decompensation in GLP-1RA vs. non-GLP-1RA patients.
0.3%
Hepatocellular Carcinoma Incidence
Incidence of hepatocellular carcinoma in GLP-1RA vs. non-GLP-1RA patients.